Mr. Hugh MacNaught reports

VENTRIPOINT ANNOUNCES CLOSING OF FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT PURSUANT TO LISTED ISSUER FINANCING EXEMPTION

Ventripoint Diagnostics Ltd. has closed the first tranche of its non-brokered private placement offering, as described in its press releases of Aug. 28, 2024, Aug. 29, 2024, Sept. 17, 2024, and Oct. 15, 2024, pursuant to the listed issuer financing exemption under Part 5A of NI 45-105 (Prospectus Exemptions), resulting in the issuance of 2,351,730 units of the company at a price of 19.5 cents per unit for aggregate gross proceeds of $458,587. The common shares and warrants issued pursuant to the LIFE offering are not subject to a hold period.

The outside date for closing both the corporation's previously announced convertible debenture offering and the LIFE offering has been extended to Nov. 12, 2024. The convertible debenture offering and LIFE offering remain subject to certain conditions including, but not limited to, receipt of all necessary approvals including approval of the TSX Venture Exchange.

There is an offering document related to the LIFE offering that can be accessed under the company's profile on SEDAR+ and on the company's website. Prospective investors should read this offering document before making an investment decision.

The corporation will use the proceeds of the offering to finance operational costs related sales and marketing, additional key staff and for general working capital purposes.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

We seek Safe Harbor.